免疫球蛋白E
缺氧(环境)
肺
抗体
医学
下调和上调
肺动脉高压
免疫学
受体
药理学
化学
生物
内科学
基因
生物化学
有机化学
氧气
作者
Ting Shu,Ying Li,Yitian Zhou,Zhou Zhou,Bolun Li,Yanjiang Xing,Peiran Yang,Junling Pang,Jinqiu Li,Xiaomin Song,Xin Ning,Xianmei Qi,Chao Xiong,Hang Yang,Qianlong Chen,Jingyu Chen,Ying Yu,Jing Wang,Chen Wang
标识
DOI:10.1038/s44161-022-00095-9
摘要
Pulmonary hypertension (PH) is a severe cardiopulmonary disease characterized by pulmonary vascular remodeling. Immunoglobulin E (IgE) is known to participate in aortic vascular remodeling, but whether IgE mediates pulmonary vascular disease is unknown. In the present study, we found serum IgE elevation in pulmonary arterial hypertension (PAH) patients, hypoxia-induced PH mice and monocrotaline-induced PH rats. Neutralizing IgE with an anti-IgE antibody was effective in preventing PH development in mice and rat models. The IgE receptor FcεRIα was also upregulated in PH lung tissues and Fcer1a deficiency prevented the development of PH. Single-cell RNA-sequencing revealed that FcεRIα was mostly expressed in mast cells (MCs) and MC-specific Fcer1a knockout protected against PH in mice. IgE-activated MCs produced interleukin (IL)-6 and IL-13, which subsequently promoted vascular muscularization. Clinically approved IgE antibody omalizumab alleviated the progression of established PH in rats. Using genetic and pharmacological approaches, we have demonstrated that blocking IgE–FcεRIα signaling may hold potential for PAH treatment. Using rat and mouse models of pulmonary hypertension and patients’ data, Shu, Liu, Zhou et al. show that the concomitant increase in immunoglobulin E (IgE) and mast cells expressing the effector receptor FcεRIα has an important role in pulmonary vascular remodeling, and genetic and pharmacological inhibition of the IgE–FcεRIα signaling alleviated the progression of pulmonary hypertension in animal models.
科研通智能强力驱动
Strongly Powered by AbleSci AI